



PHARMACEUTICAL 2023











PHARMACEUTICAL 2023



NexImmune Inc. Rank 323 of 446

The relative strengths and weaknesses of NexImmune Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NexImmune Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 27% points. The greatest weakness of NexImmune Inc. is the variable Net Income, reducing the Economic Capital Ratio by 134% points.

The company's Economic Capital Ratio, given in the ranking table, is -26%, being 69% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	37,369
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,334
Liabilities, Non-Current	426
Other Assets	1,232
Other Compr. Net Income	-3.0
Other Expenses	0
Other Liabilities	0
Other Net Income	577
Other Revenues	0
Property and Equipment	4,459
Research and Development	47,148
Selling, General and Administrative Expense	15,934

Output Variable	Value in 1000 USD
Assets	43,060
Liabilities	10,759
Expenses	63,083
Revenues	0
Stockholders Equity	32,300
Net Income	-62,506
Comprehensive Net Income	-62,508
Economic Capital Ratio	-26%

